RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Devoro Medical

Company

Content

Owners

Devoro Medical is the developer of a medical device designed to restore blood flow. The company was founded in 2018. Employees 25.

History

2021: Boston Scientific bought Devoro Medical

At the end of September 2021, Boston Scientific announced the acquisition of Devoro Medical in a deal worth $269 million, continuing to spend funds on mergers and acquisitions in the field of medical technology. The deal is expected to close in the fourth quarter of 2021.

Devoro Medical manufactures the WOLF thrombectomy platform, which is designed to capture and break blood clots with finger-shaped teeth, and then swallow or suck the clot into the device. Boston Scientific has been a strategic investor in Devoro since 2019, owning approximately 16% of the shares. The acquisition will give Boston Scientific the remaining 84% stake. A thrombectomy device for removing a thrombus from a occluded large intracranial vessel into patients with acute ischemic stroke. The device may be used alone or as a supplement to intravenous administration of tissue plasminogen activator (tPA) and or other conventional modality thrombectomy.

Boston Scientific buys developer of blood clot removal system

Boston Scientific Chief Physician and Vice President Michael Jaff for Peripheral Interventions, said on September 21, 2021, that the company plans to accelerate the development of WOLF technology after acquisition. The Boston Scientific model in 2021 was to buy the remaining shares of the companies after the initial investment, because the company bought back shares from Prevention, Farapulse, and now Devoro Medical.

Prior to consideration of current interest, debt and other adjustments at the close of the transaction, the transaction price consists of $320 million in advance and up to $80 million when reaching certain clinical and regulatory indicators.

Market analysts in this area added that competition in the peripheral thrombectomy market will intensify, as market penetration is only about 10%, and doctors prefer thrombectomy methods such as WOLF technology.[1]

Notes